Jakob Einhaus and colleagues first tested the drugs on immune cells from blood samples donated by pregnant and non-pregnant people. The nine interventions were chlorthalidone, maprotiline, metformin, lansoprazole, pravastatin, rifabutin, salicylic acid, salicylic acid plus lansoprazole, and 5-methyltetrahydrofolate, a form of folic acid. The researchers established the effects of these treatments on the cells in vitro, then combined those results with a second set of untreated samples to relate molecular immune activity to gestational age at delivery. That second dataset included samples from 11 pregnant participants, while eight non-pregnant people served as controls.

By integrating the two experiments, the researchers constructed SIMCO’s digital twins to replicate how the drugs altered labor-related immune-cell activity. Under the model, tetrahydrofolate and the salicylic-acid-plus-lansoprazole combination had the greatest potential to delay labor onset. The other seven drugs initially produced a counterproductive response in the model, appearing to speed labor-related changes before slowing them. These findings are computational estimates based on laboratory observations and a small donor dataset; they are not clinical-trial outcomes, and the study did not establish that the candidate drugs would delay delivery when administered during pregnancy.

The work was presented as a possible response to the limited number of prenatal interventions available for pregnancy complications. According to the research summary, trials in this area face ethical difficulties, restrictive regulations and underfunding. A related Focus noted that the therapeutic gap reflects scientific challenges as well as a history of tragic failures in treating pregnant people. SIMCO offers a way to evaluate how existing drugs might affect labor-associated immune activity using experimental and human sample data. Its shortlist may help direct further investigation, but the published evidence remains a modeling study rather than proof of clinical benefit.

Subject of Research: Digital-twin screening of approved drugs for potential preterm-labor prevention

Article Title: Two out of nine FDA-approved drugs could slow preterm labor, new digital twin model suggests

Article References: Two out of nine FDA-approved drugs could slow preterm labor, new digital twin model suggests. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: preterm labor, digital twins, SIMCO, drug screening, immune cells, pregnancy, folic acid, aspirin, lansoprazole, single-cell modeling, nine, FDA-approved